Seeking Alpha

Amgen (AMGN) is due to plead guilty today in an investigation into its business practices, the...

Amgen (AMGN) is due to plead guilty today in an investigation into its business practices, the U.S. attorney's office says, with the NYT reporting that the company will admit to mis-branding, which usually means promoting drugs for non-approved uses. Amgen will pay a fine close to the $780M it has set aside to cover the allegations, of which $150M will be for a criminal penalty.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs